SCHEMBL6436787

SCHEMBL6436787

Cc1nc(O)c2c(n1)CCN(c1nc(C)nc(O)c1[N+](=O)[O-])CC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
HTT P42858 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP3A4 P08684 1/20 0.32
TRPV1 Q8NER1 3/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
NR4A1 P22736 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949469 0.80 POLB (0.43) HTTCYP1A2CYP2C9CYP2C19POLB
SCHEMBL6435503 0.78 HTT (0.33) ALDH1A1HTTCYP1A2CYP2C9CYP2C19
SCHEMBL596867 0.70 TDP1 (0.38) ALDH1A1HTTPOLBMAPTMEN1
SCHEMBL1123936 0.67 ALDH1A1 (0.63) ALDH1A1HTTCYP1A2CYP2C9CYP2C19
SCHEMBL18711840 0.66 HTR2A (0.31)
SCHEMBL6947517 0.66 MEN1 (0.44) ALDH1A1HTTCYP1A2CYP2C9CYP2C19
SCHEMBL7078865 0.65 MAPT (0.37) ALDH1A1HTTPOLBMAPTMAPK1
SCHEMBL5773495 0.64 HTT (0.52) ALDH1A1HTTCYP1A2CYP2C9CYP2C19
SCHEMBL9121667 0.63 MAPT (0.44) ALDH1A1HTTCYP1A2CYP2C9CYP2C19
SCHEMBL9122461 0.63 MAPT (0.47) ALDH1A1HTTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303521-B1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-02-02 EP claimed
US-20020045635-A1 Novel mGluR antagonists and a method for their synthesis HOFFMANN-LA ROCHE, INC. 2002-04-18 US claimed
US-6369222-B1 NITRO- AND CYANO-1,2,4,5-TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES; BRAIN, EYE, MUSCULAR, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2002-04-09 US claimed
EP-1303521-B1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-02-02 EP disclosed
EP-1303521-A1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020045635-A1 Novel mGluR antagonists and a method for their synthesis HOFFMANN-LA ROCHE, INC. 2002-04-18 US disclosed
US-6369222-B1 NITRO- AND CYANO-1,2,4,5-TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES; BRAIN, EYE, MUSCULAR, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2002-04-09 US disclosed
WO-2002006288-A1 TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045635-A1 Novel mGluR antagonists and a method for their synthesis GRM1, GRM5, GRM2 ALDH1A1 3041/4885HTT 2707/4885CYP1A2 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.